Characterization of the unusual antinociceptive profile of tramadol in mice

A. Mattia, Todd W Vanderah, R. B. Raffa, J. L. Vaught, R. J. Tallarida, Frank Porreca

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The present study characterized the antinociceptive effects of tramadol with emphasis on the site of action, the possible development of antinociceptive tolerance, and possible cross-tolerance to morphine. Both tramadol and morphine produced antinociception as assessed in male, ICR mice using the warm water (55°C) tail-flick test. Intrathecal (i.t.) tramadol produced an antinociceptive response, but with a shallow dose-response curve (DRC), but i.c.v. tramadol was ineffective up to toxic doses (> 380 nmol). Simultaneous co-administration of tramadol by the i.c.v. and i.t. routes in a 1:1 fixed dose-ratio resulted in a synergistic interaction. Construction of a naloxone dose-response curve against an A90 dose of agonist yielded an AD50 (and 95% C.L.) of 0.19 (0.14-0.33) and 0.55 (0.38-0.74) μmol/kg against morphine and tramadol, respectively; both agonists were completely antagonized by naloxone. In mice pretreated twice daily (8:00 a.m. and 5:00 p.m.) with s.c. morphine the DRC for morphine was displaced 16-fold to the right, indicating significant development of antinociceptive tolerance. The same pretreatment resulted in only a 3-fold rightward shift in the tramadol DRC. Chronic twice-daily (8:00 a.m. and 5:00 p.m.) pretreatment with tramadol resulted in only an approximate 3- and 4-fold rightward displacement in the tramadol and morphine DRCs, respectively. These results suggest that tramadol has an unusual antinociceptive mechanism which may reflect a primary site of action at spinal sites with a synergistic spinal/supraspinal interaction. Further, the lack of complete cross-tolerance between tramadol and morphine supports the suggestion of a non-opioid mechanism for this compound, whereas the complete antagonism by naloxone apparently reflects the opioid component of its mechanism in this test. Finally, the minimal development of tolerance to tramadol antinociception reinforces the view of a favorable tolerance-dependence profile for this compound.

Original languageEnglish (US)
Pages (from-to)176-182
Number of pages7
JournalDrug Development Research
Volume28
Issue number2
StatePublished - 1993

Fingerprint

Tramadol
Morphine
Naloxone
Inbred ICR Mouse
Poisons
Opioid Analgesics
Tail

Keywords

  • Antinociception
  • Brain
  • Mice
  • Spinal cord
  • Tramadol

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

Characterization of the unusual antinociceptive profile of tramadol in mice. / Mattia, A.; Vanderah, Todd W; Raffa, R. B.; Vaught, J. L.; Tallarida, R. J.; Porreca, Frank.

In: Drug Development Research, Vol. 28, No. 2, 1993, p. 176-182.

Research output: Contribution to journalArticle

Mattia, A, Vanderah, TW, Raffa, RB, Vaught, JL, Tallarida, RJ & Porreca, F 1993, 'Characterization of the unusual antinociceptive profile of tramadol in mice', Drug Development Research, vol. 28, no. 2, pp. 176-182.
Mattia, A. ; Vanderah, Todd W ; Raffa, R. B. ; Vaught, J. L. ; Tallarida, R. J. ; Porreca, Frank. / Characterization of the unusual antinociceptive profile of tramadol in mice. In: Drug Development Research. 1993 ; Vol. 28, No. 2. pp. 176-182.
@article{876f8be065c14b3282ac4221da5c2a93,
title = "Characterization of the unusual antinociceptive profile of tramadol in mice",
abstract = "The present study characterized the antinociceptive effects of tramadol with emphasis on the site of action, the possible development of antinociceptive tolerance, and possible cross-tolerance to morphine. Both tramadol and morphine produced antinociception as assessed in male, ICR mice using the warm water (55°C) tail-flick test. Intrathecal (i.t.) tramadol produced an antinociceptive response, but with a shallow dose-response curve (DRC), but i.c.v. tramadol was ineffective up to toxic doses (> 380 nmol). Simultaneous co-administration of tramadol by the i.c.v. and i.t. routes in a 1:1 fixed dose-ratio resulted in a synergistic interaction. Construction of a naloxone dose-response curve against an A90 dose of agonist yielded an AD50 (and 95{\%} C.L.) of 0.19 (0.14-0.33) and 0.55 (0.38-0.74) μmol/kg against morphine and tramadol, respectively; both agonists were completely antagonized by naloxone. In mice pretreated twice daily (8:00 a.m. and 5:00 p.m.) with s.c. morphine the DRC for morphine was displaced 16-fold to the right, indicating significant development of antinociceptive tolerance. The same pretreatment resulted in only a 3-fold rightward shift in the tramadol DRC. Chronic twice-daily (8:00 a.m. and 5:00 p.m.) pretreatment with tramadol resulted in only an approximate 3- and 4-fold rightward displacement in the tramadol and morphine DRCs, respectively. These results suggest that tramadol has an unusual antinociceptive mechanism which may reflect a primary site of action at spinal sites with a synergistic spinal/supraspinal interaction. Further, the lack of complete cross-tolerance between tramadol and morphine supports the suggestion of a non-opioid mechanism for this compound, whereas the complete antagonism by naloxone apparently reflects the opioid component of its mechanism in this test. Finally, the minimal development of tolerance to tramadol antinociception reinforces the view of a favorable tolerance-dependence profile for this compound.",
keywords = "Antinociception, Brain, Mice, Spinal cord, Tramadol",
author = "A. Mattia and Vanderah, {Todd W} and Raffa, {R. B.} and Vaught, {J. L.} and Tallarida, {R. J.} and Frank Porreca",
year = "1993",
language = "English (US)",
volume = "28",
pages = "176--182",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Characterization of the unusual antinociceptive profile of tramadol in mice

AU - Mattia, A.

AU - Vanderah, Todd W

AU - Raffa, R. B.

AU - Vaught, J. L.

AU - Tallarida, R. J.

AU - Porreca, Frank

PY - 1993

Y1 - 1993

N2 - The present study characterized the antinociceptive effects of tramadol with emphasis on the site of action, the possible development of antinociceptive tolerance, and possible cross-tolerance to morphine. Both tramadol and morphine produced antinociception as assessed in male, ICR mice using the warm water (55°C) tail-flick test. Intrathecal (i.t.) tramadol produced an antinociceptive response, but with a shallow dose-response curve (DRC), but i.c.v. tramadol was ineffective up to toxic doses (> 380 nmol). Simultaneous co-administration of tramadol by the i.c.v. and i.t. routes in a 1:1 fixed dose-ratio resulted in a synergistic interaction. Construction of a naloxone dose-response curve against an A90 dose of agonist yielded an AD50 (and 95% C.L.) of 0.19 (0.14-0.33) and 0.55 (0.38-0.74) μmol/kg against morphine and tramadol, respectively; both agonists were completely antagonized by naloxone. In mice pretreated twice daily (8:00 a.m. and 5:00 p.m.) with s.c. morphine the DRC for morphine was displaced 16-fold to the right, indicating significant development of antinociceptive tolerance. The same pretreatment resulted in only a 3-fold rightward shift in the tramadol DRC. Chronic twice-daily (8:00 a.m. and 5:00 p.m.) pretreatment with tramadol resulted in only an approximate 3- and 4-fold rightward displacement in the tramadol and morphine DRCs, respectively. These results suggest that tramadol has an unusual antinociceptive mechanism which may reflect a primary site of action at spinal sites with a synergistic spinal/supraspinal interaction. Further, the lack of complete cross-tolerance between tramadol and morphine supports the suggestion of a non-opioid mechanism for this compound, whereas the complete antagonism by naloxone apparently reflects the opioid component of its mechanism in this test. Finally, the minimal development of tolerance to tramadol antinociception reinforces the view of a favorable tolerance-dependence profile for this compound.

AB - The present study characterized the antinociceptive effects of tramadol with emphasis on the site of action, the possible development of antinociceptive tolerance, and possible cross-tolerance to morphine. Both tramadol and morphine produced antinociception as assessed in male, ICR mice using the warm water (55°C) tail-flick test. Intrathecal (i.t.) tramadol produced an antinociceptive response, but with a shallow dose-response curve (DRC), but i.c.v. tramadol was ineffective up to toxic doses (> 380 nmol). Simultaneous co-administration of tramadol by the i.c.v. and i.t. routes in a 1:1 fixed dose-ratio resulted in a synergistic interaction. Construction of a naloxone dose-response curve against an A90 dose of agonist yielded an AD50 (and 95% C.L.) of 0.19 (0.14-0.33) and 0.55 (0.38-0.74) μmol/kg against morphine and tramadol, respectively; both agonists were completely antagonized by naloxone. In mice pretreated twice daily (8:00 a.m. and 5:00 p.m.) with s.c. morphine the DRC for morphine was displaced 16-fold to the right, indicating significant development of antinociceptive tolerance. The same pretreatment resulted in only a 3-fold rightward shift in the tramadol DRC. Chronic twice-daily (8:00 a.m. and 5:00 p.m.) pretreatment with tramadol resulted in only an approximate 3- and 4-fold rightward displacement in the tramadol and morphine DRCs, respectively. These results suggest that tramadol has an unusual antinociceptive mechanism which may reflect a primary site of action at spinal sites with a synergistic spinal/supraspinal interaction. Further, the lack of complete cross-tolerance between tramadol and morphine supports the suggestion of a non-opioid mechanism for this compound, whereas the complete antagonism by naloxone apparently reflects the opioid component of its mechanism in this test. Finally, the minimal development of tolerance to tramadol antinociception reinforces the view of a favorable tolerance-dependence profile for this compound.

KW - Antinociception

KW - Brain

KW - Mice

KW - Spinal cord

KW - Tramadol

UR - http://www.scopus.com/inward/record.url?scp=0027462096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027462096&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027462096

VL - 28

SP - 176

EP - 182

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 2

ER -